緑内障治療市場：適応症別、タイプ別、販売チャネル別-2025年～2030年の世界予測

緑内障治療市場は、2023年に67億3,000万米ドルと評価され、2024年には73億1,000万米ドルに達すると予測され、CAGR 8.94％で成長し、2030年には122億7,000万米ドルに達すると予測されています。

緑内障治療市場は、不可逆的な失明の主な原因を管理するために重要であり、主に眼圧を下げ、視神経機能を維持することを目的とした様々な治療法や機器を包含しています。緑内障の有病率の上昇と世界人口の高齢化に伴い、効果的な治療ソリューションの必要性が拡大しています。市場の応用範囲は薬物療法（プロスタグランジンアナログ、β遮断薬、α作動薬、炭酸脱水酵素阻害薬）、レーザー療法、外科的介入（トラベクレクトミー、ドレナージインプラント）に及び、エンドユーザーは主に眼科クリニック、病院、研究機関などです。市場成長の原動力となっているのは、ドラッグデリバリーシステムにおける技術革新の進展、早期診断に対する意識の高まり、より良い疾患管理のための人工知能の導入などです。しかし、高い治療費と潜在的な副作用が課題となっており、患者の治療レジメンへのアドヒアランス向上が求められています。

新規治療薬や個別化医療アプローチの開発には大きなビジネスチャンスがあり、これは業界の精密治療へのシフトに沿ったものです。企業はバイオテクノロジー部門との提携を模索し、徐放性薬剤製剤や低侵襲デバイスに焦点を当てた臨床試験に投資することができます。とはいえ、規制上のハードルや長い承認プロセスが市場力学を制約する可能性があり、合理化された承認ワークフローの必要性が強調されています。非侵襲的診断・治療モニタリングツールの革新は、大きな成長の可能性を秘めています。さらに、ヘルスケア・インフラが拡大する新興市場への参入は、収益性の高い事業となります。このような機会にもかかわらず、知的財産の問題や発展途上地域でのアクセス制限といった課題は依然として残っており、戦略的な適応が必要です。市場の競争と技術進歩のペースを理解することが重要です。その結果、企業はこの絶えず進化する状況の中で一歩先を行くために、強力な研究開発イニシアチブを育成し、最先端の研究革新のために学術機関との協力を検討しなければならないです。このような多面的なアプローチは、市場での地位を強化するだけでなく、治療効率と患者の転帰を向上させる。

市場力学：急速に進化する緑内障治療市場の主要市場インサイトを公開

緑内障治療市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 緑内障罹患率の上昇と相俟って増加する老人人口
  • 緑内障に対する認識を高めるための政府および製薬団体のイニシアチブの高まり
  • 人口のスマートガジェットの使用とスクリーンタイムの増加の可能性
• 市場抑制要因
  • 低開発国における早期診断の欠如
• 市場機会
  • 点眼薬の継続的な技術進歩
  • 製薬会社やバイオテクノロジー企業による研究開発の活発化（緑内障治療）
• 市場の課題
  • 医薬品回収に関する懸念

ポーターの5つの力：緑内障治療市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：緑内障治療市場における外部からの影響の把握

外部マクロ環境要因は、緑内障治療市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析緑内障治療市場における競合情勢の把握

緑内障治療市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス緑内障治療市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、緑内障治療市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨緑内障治療市場における成功への道筋を描く

緑内障治療市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 高齢者人口の増加と緑内障の発症率の上昇
    • 緑内障に対する意識を高める政府と製薬団体の取り組みが拡大
    • スマートガジェットの使用とスクリーンタイムの潜在的な増加
  • 抑制要因
    • 発展途上国における早期診断の欠如
  • 機会
    • 点眼薬の技術革新は続く
    • 製薬業界や医療業界の研究開発活動の増加

緑内障治療のバイオテクノロジー企業

• 課題
  • 医薬品リコールに関する懸念
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 緑内障治療市場：適応症別

• 閉塞隅角緑内障
• 先天性緑内障
• 開放隅角緑内障
• 続発性緑内障

第7章 緑内障治療市場：タイプ別

• アルファアゴニスト
• ベータ遮断薬
• 炭酸脱水酵素阻害剤
• コリン作動性
• 併用薬
• プロスタグランジン類似体

第8章 緑内障治療市場：販売チャネル別

• 病院薬局
• オンライン販売
• 小売薬局

第9章 南北アメリカの緑内障治療市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋の緑内障治療市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの緑内障治療市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• AbbVie Inc.
• Accutome, Inc.
• Akorn Operating Company LLC
• Alcon Vision LLC
• Amorphex Therapeutics LLC
• ASICO LLC
• Bausch+Lomb Corporation
• Bayer AG
• Carl Zeiss Meditec AG
• Fera Pharmaceuticals, LLC
• Glaukos Corporation
• Inotek Pharmaceuticals
• Lumenis Be Ltd.
• Merck & Co, Inc.
• Mobius Therapeutics, LLC
• NIDEK CO., LTD.
• Novartis AG
• Ocular Therapeutix, Inc.
• Perrigo Company PLC
• Pfizer, Inc.
• Quantel Medical
• Santen Pharmaceutical Co., Ltd.
• Teva Pharmaceutical Industries Ltd.
• Topcon Corporation

LIST OF FIGURES

• FIGURE 1. GLAUCOMA TREATMENT MARKET RESEARCH PROCESS
• FIGURE 2. GLAUCOMA TREATMENT MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS GLAUCOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS GLAUCOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC GLAUCOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC GLAUCOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. GLAUCOMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. GLAUCOMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. GLAUCOMA TREATMENT MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. GLAUCOMA TREATMENT MARKET DYNAMICS
• TABLE 7. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY ANGLE CLOSURE GLAUCOMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY CONGENITAL GLAUCOMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY OPEN ANGLE GLAUCOMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY SECONDARY GLAUCOMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY ALPHA AGONIST, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY BETA BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY CHOLINERGIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY COMBINED MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY PROSTAGLANDIN ANALOGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY ONLINE SALES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL GLAUCOMA TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS GLAUCOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 28. ARGENTINA GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 30. BRAZIL GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 31. BRAZIL GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 32. BRAZIL GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 33. CANADA GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 34. CANADA GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 35. CANADA GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 36. MEXICO GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 37. MEXICO GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 38. MEXICO GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 39. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 40. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 41. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 42. UNITED STATES GLAUCOMA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 43. ASIA-PACIFIC GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 44. ASIA-PACIFIC GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 45. ASIA-PACIFIC GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 46. ASIA-PACIFIC GLAUCOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 47. AUSTRALIA GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 48. AUSTRALIA GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 49. AUSTRALIA GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 50. CHINA GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 51. CHINA GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 52. CHINA GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 53. INDIA GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 54. INDIA GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 55. INDIA GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 56. INDONESIA GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 57. INDONESIA GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 58. INDONESIA GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 59. JAPAN GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 60. JAPAN GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 61. JAPAN GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 62. MALAYSIA GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 63. MALAYSIA GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 64. MALAYSIA GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 65. PHILIPPINES GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 66. PHILIPPINES GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 67. PHILIPPINES GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 68. SINGAPORE GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 69. SINGAPORE GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 70. SINGAPORE GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 71. SOUTH KOREA GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 72. SOUTH KOREA GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 73. SOUTH KOREA GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 74. TAIWAN GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 75. TAIWAN GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 76. TAIWAN GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 77. THAILAND GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 78. THAILAND GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 79. THAILAND GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 80. VIETNAM GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 81. VIETNAM GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 82. VIETNAM GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 83. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 84. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 85. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 86. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 87. DENMARK GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 88. DENMARK GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 89. DENMARK GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 90. EGYPT GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 91. EGYPT GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 92. EGYPT GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 93. FINLAND GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 94. FINLAND GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 95. FINLAND GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 96. FRANCE GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 97. FRANCE GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 98. FRANCE GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 99. GERMANY GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 100. GERMANY GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 101. GERMANY GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 102. ISRAEL GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 103. ISRAEL GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 104. ISRAEL GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 105. ITALY GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 106. ITALY GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 107. ITALY GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 108. NETHERLANDS GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 109. NETHERLANDS GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 110. NETHERLANDS GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 111. NIGERIA GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 112. NIGERIA GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 113. NIGERIA GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 114. NORWAY GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 115. NORWAY GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 116. NORWAY GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 117. POLAND GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 118. POLAND GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 119. POLAND GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 120. QATAR GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 121. QATAR GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 122. QATAR GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 123. RUSSIA GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 124. RUSSIA GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 125. RUSSIA GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 126. SAUDI ARABIA GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 127. SAUDI ARABIA GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 128. SAUDI ARABIA GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 129. SOUTH AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 130. SOUTH AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 131. SOUTH AFRICA GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 132. SPAIN GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 133. SPAIN GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 134. SPAIN GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 135. SWEDEN GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 136. SWEDEN GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 137. SWEDEN GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 138. SWITZERLAND GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 139. SWITZERLAND GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 140. SWITZERLAND GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 141. TURKEY GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 142. TURKEY GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 143. TURKEY GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 144. UNITED ARAB EMIRATES GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 145. UNITED ARAB EMIRATES GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 146. UNITED ARAB EMIRATES GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 147. UNITED KINGDOM GLAUCOMA TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 148. UNITED KINGDOM GLAUCOMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 149. UNITED KINGDOM GLAUCOMA TREATMENT MARKET SIZE, BY SALES CHANNEL, 2018-2030 (USD MILLION)
• TABLE 150. GLAUCOMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 151. GLAUCOMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

The Glaucoma Treatment Market was valued at USD 6.73 billion in 2023, expected to reach USD 7.31 billion in 2024, and is projected to grow at a CAGR of 8.94%, to USD 12.27 billion by 2030.

The glaucoma treatment market, crucial for managing a leading cause of irreversible blindness, predominantly encompasses various therapies and devices aimed at reducing intraocular pressure and preserving optic nerve function. With the rising prevalence of glaucoma and an aging global population, the necessity for effective treatment solutions is expanding. The market's application scope spans medication (prostaglandin analogs, beta blockers, alpha agonists, carbonic anhydrase inhibitors), laser therapy, and surgical interventions (trabeculectomy and drainage implants), while end-users primarily include ophthalmology clinics, hospitals, and research institutes. Market growth is fueled by advancing innovations in drug delivery systems, increased awareness of early diagnosis, and the incorporation of artificial intelligence for better disease management. However, high treatment costs and potential side effects pose challenges, alongside the need for improved patient adherence to treatment regimens.

There are significant opportunities in the development of novel therapeutic agents and personalized medicine approaches, which align with the industry's shift towards precision treatment. Companies can explore partnerships within the biotech sector and invest in clinical trials focusing on sustained-release drug formulations and minimally invasive devices. Nevertheless, regulatory hurdles and lengthy approval processes can constrain market dynamics, emphasizing the need for streamlined approval workflows. Innovating within non-invasive diagnosis and treatment monitoring tools presents substantial growth potential. Further, tapping into emerging markets with expanding healthcare infrastructure offers profitable ventures. Despite these opportunities, persistent challenges such as intellectual property issues and limited accessibility in developing regions require strategic adaptation. Comprehending the competitive nature of the market and the pace of technological advancements is critical. Consequently, businesses must foster robust R&D initiatives to stay ahead in this constantly evolving landscape and consider collaborations with academic institutions for cutting-edge research innovations. This multi-faceted approach not only fortifies market position but also enhances treatment efficiency and patient outcomes.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Glaucoma Treatment Market

The Glaucoma Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing geriatric population coupled with rising incidences of glaucoma
  • Growing government and pharmaceutical organizations initiatives to increase awareness on glaucoma
  • Potential rise in the use of smart gadgets and screen time among the population
• Market Restraints
  • Lack of early diagnosis in underdeveloped economies
• Market Opportunities
  • Ongoing technological advancement with eye drops
  • Increasing research and development activities from pharmaceutical and biotechnological companies for glaucoma treatment
• Market Challenges
  • Concerns associated with drug recalls

Porter's Five Forces: A Strategic Tool for Navigating the Glaucoma Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Glaucoma Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Glaucoma Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Glaucoma Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Glaucoma Treatment Market

A detailed market share analysis in the Glaucoma Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Glaucoma Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Glaucoma Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Glaucoma Treatment Market

A strategic analysis of the Glaucoma Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Glaucoma Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Accutome, Inc., Akorn Operating Company LLC, Alcon Vision LLC, Amorphex Therapeutics LLC, ASICO LLC, Bausch + Lomb Corporation, Bayer AG, Carl Zeiss Meditec AG, Fera Pharmaceuticals, LLC, Glaukos Corporation, Inotek Pharmaceuticals, Lumenis Be Ltd., Merck & Co, Inc., Mobius Therapeutics, LLC, NIDEK CO., LTD., Novartis AG, Ocular Therapeutix, Inc., Perrigo Company PLC, Pfizer, Inc., Quantel Medical, Santen Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Ltd., and Topcon Corporation.

Market Segmentation & Coverage

This research report categorizes the Glaucoma Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Indication, market is studied across Angle Closure Glaucoma, Congenital Glaucoma, Open Angle Glaucoma, and Secondary Glaucoma.
• Based on Type, market is studied across Alpha Agonist, Beta Blockers, Carbonic Anhydrase Inhibitors, Cholinergic, Combined Medications, and Prostaglandin Analogs.
• Based on Sales Channel, market is studied across Hospital Pharmacies, Online Sales, and Retail Pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing geriatric population coupled with rising incidences of glaucoma
    • 5.1.1.2. Growing government and pharmaceutical organizations initiatives to increase awareness on glaucoma
    • 5.1.1.3. Potential rise in the use of smart gadgets and screen time among the population
  • 5.1.2. Restraints
    • 5.1.2.1. Lack of early diagnosis in underdeveloped economies
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing technological advancement with eye drops
    • 5.1.3.2. Increasing research and development activities from pharmaceutical and

biotechnological companies for glaucoma treatment

• 5.1.4. Challenges
  • 5.1.4.1. Concerns associated with drug recalls
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Glaucoma Treatment Market, by Indication

• 6.1. Introduction
• 6.2. Angle Closure Glaucoma
• 6.3. Congenital Glaucoma
• 6.4. Open Angle Glaucoma
• 6.5. Secondary Glaucoma

7. Glaucoma Treatment Market, by Type

• 7.1. Introduction
• 7.2. Alpha Agonist
• 7.3. Beta Blockers
• 7.4. Carbonic Anhydrase Inhibitors
• 7.5. Cholinergic
• 7.6. Combined Medications
• 7.7. Prostaglandin Analogs

8. Glaucoma Treatment Market, by Sales Channel

• 8.1. Introduction
• 8.2. Hospital Pharmacies
• 8.3. Online Sales
• 8.4. Retail Pharmacies

9. Americas Glaucoma Treatment Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Glaucoma Treatment Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Glaucoma Treatment Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. Accutome, Inc.
• 3. Akorn Operating Company LLC
• 4. Alcon Vision LLC
• 5. Amorphex Therapeutics LLC
• 6. ASICO LLC
• 7. Bausch + Lomb Corporation
• 8. Bayer AG
• 9. Carl Zeiss Meditec AG
• 10. Fera Pharmaceuticals, LLC
• 11. Glaukos Corporation
• 12. Inotek Pharmaceuticals
• 13. Lumenis Be Ltd.
• 14. Merck & Co, Inc.
• 15. Mobius Therapeutics, LLC
• 16. NIDEK CO., LTD.
• 17. Novartis AG
• 18. Ocular Therapeutix, Inc.
• 19. Perrigo Company PLC
• 20. Pfizer, Inc.
• 21. Quantel Medical
• 22. Santen Pharmaceutical Co., Ltd.
• 23. Teva Pharmaceutical Industries Ltd.
• 24. Topcon Corporation